ClinicalTrials.gg
RecruitingNCT07102251Updated Nov 5, 2026

A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects

A Phase 1 interventional study of HEC-007 injection and Placebo in Healthy Subjects, sponsored by Sunshine Lake Pharma Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose administration in healthy subjects and multiple-dose administration in overweight or obese subjects.

The trial consists of two parts: Part A is a single ascending dose (SAD) study, planning to enroll 54 Chinese healthy subjects; Part B is a multiple ascending dose (MAD) study, planning to enroll 72 Chinese overweight or obese subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

SAD

  1. Subjects understand and comply with the study procedures, voluntarily participate, and sign the form.
  2. Healthy adult subjects (including borderline values) aged 18 to 45 years, regardless of sex.
  3. Male subjects weigh no less than 50 kg, and female subjects weigh no less than 45 kg. =Body weight (kg)/height2 (m2), with a body mass index ranging from 19.0 to 35.0 kg/m2 (including boundary values).
  4. Normal results or abnormalities deemed clinically insignificant by the investigator in vital signs, physical examination, laboratory tests, , chest CT, abdominal ultrasound (liver, gallbladder, spleen, pancreas, and both kidneys), and thyroid ultrasound.
  5. Female subjects of or male subjects must agree to use effective from signing the informed consent until 6 months after the last administration of the product to avoid pregnancy or impregnating a partner, with no plans for sperm or egg donation or pregnancy.
  6. (HbA1c) \<5.7% during the screening period. MAD

1. Subjects understand and comply with the study procedures, voluntarily participate, and sign the informed consent form.

2. Age between 18 to 65 years (inclusive), both male and female. 3. Obesity: BMI ≥28.0 kg/m2; or overweight: 24.0 \<BMI \<28.0 kg/m2, and with at least one of the following manifestations: prediabetes (as detailed in 14.4), hypertension, dyslipidemia, fatty liver, weight-bearing joint pain, obesity-related dyspnea, or obstructive sleep apnea syndrome.

4. At screening, weight change of \< 5% over at least 12 weeks of diet and exercise control alone.

5. Female subjects of childbearing potential or male subjects must agree to use effective contraceptionfrom signing the informed consent until 6 months after the last administration of the investigational product to avoid pregnancy or impregnating a partner, with no plans for sperm or egg donation or pregnancy.

6. Glycated hemoglobin (HbA1c) \<6.5% during the screening period.

Exclusion criteria

Exclusion Criteria:

SAD

  1. Those diagnosed with type 1, type 2, or other types of diabetes before screening;
  2. History or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia syndrome type 2 (MEN2) during screening, or genetic predisposition to MTC;
  3. Acute, chronic, or suspected pancreatitis during screening, or prior pancreatectomy;
  4. Those diagnosed with any within 5 years before screening (except for basal cell carcinoma treated curatively and considered cured);
  5. Presence of diseases (including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular disorders) during screening;
  6. Diseases or conditions affecting gastric emptying or gastrointestinal nutrient absorption during screening;
  7. Major surgery within 3 months before screening or planned surgery during the study;
  8. History of to the product or any of its components, or allergic constitution (allergy to two or more drugs or foods).
  9. Use of medications (including prescription drugs, over-the-counter drugs, herbal medicines, health supplements, etc.) within 3 months prior to screening that, in the investigator's judgment, significantly affect weight or glucose metabolism;
  10. Individuals who have undergone bariatric surgery prior to screening;
  11. Those with a history of recurrent skin disorders (e.g., urticaria) or skin lesions at the administration site;
  12. Those who received chronic (lasting more than 2 weeks) systemic therapy (excluding topical, intraocular, intranasal, intra-articular, or inhaled formulations) within 3 months prior to screening, or systemic glucocorticoid therapy within 1 month prior to screening;
  13. Female subjects with \<110 g/L or male subjects with HbA1c \<120 g/L at screening, or any other known condition that interferes with HbA1c measurement;
  14. Those with suicidal behaviors or ideation within 6 months prior to screening;
  15. Use of GLP-1R, GLP-1R/GIPR, GLP-1R/GCGR, or GLP-1R/GIPR/GCGR agonists within 6 months prior to screening;
  16. Those with regular alcohol consumption within 3 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360 mL beer, 45 mL spirits with 40% alcohol, or 150 mL wine); or those with a positive alcohol breath test during screening; or those unable to comply with the protocol's alcohol restrictions;
  17. Those with a history of drug abuse or illicit drug use within 2 years prior to screening, or those with a positive urine drug screen before administration;
  18. Smoking more than 5 cigarettes per day within 3 months prior to screening or inability to abstain from smoking during intensive PK blood sampling;
  19. Those with a history of needle or blood phobia, intolerance to venipuncture, or difficulty in blood collection;
  20. Those with positive results for surface antigen (HBsAg), virus (HCV) antibody, (HIV) antibody, or Treponema pallidum-specific antibody;
  21. >1.5 × (ULN), aspartate aminotransferase >1.5 × ULN, alkaline phosphatase >1.5 × ULN, or total >1.5 × ULN at screening;
  22. Those with blood amylase or lipase > ULN at screening;
  23. Those with serum calcitonin ≥20 ng/L at screening;
  24. Those with fasting blood glucose ≥6.1 mmol/L or \<3.9 mmol/L at screening;
  25. Those with (GFR) \<90 mL/min/1.73m2 at screening;
  26. Fridericia- interval (QTcF=QT/RR0.33) >450 ms (for male) or >470 ms (for female) on 12-lead at screening;
  27. Use of strong inhibitors or inducers of hepatic metabolic enzymes (CYP1A2, 2A6, 2C8, 2C19, 3A4, and 3A5) within 4 weeks prior to the first dose, including strong inhibitors such as ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, troleandomycin, etc., or strong inducers such as rifampin, carbamazepine, phenytoin sodium, St. John's wort, etc.;
  28. Use of any prescription drugs, over-the-counter medications, vitamin products, or Chinese herbal medicines within 2 weeks prior to the first dose;
  29. Consumption of any foods or beverages affecting , CYP2E1, or CYP2D6 metabolic enzymes, such as grapefruit or grapefruit-containing beverages, within 48 hours prior to the first dose;
  30. Ingestion of chocolate, any caffeine-containing or xanthine-rich food or beverage within 48 hours prior to the first dose;
  31. Blood donation ≥200 mL, any component blood donation, or total blood loss ≥200 mL due to any reason within 3 months prior to screening, or a history of blood transfusion or blood product use;
  32. Participation in other clinical trials within 3 months prior to screening (subjects who withdrew from the study before treatment, i.e., were not randomized or did not receive treatment, may be enrolled in this study);
  33. Occurrence of acute illness or concomitant medication use from the signing of the form until the first dose;
  34. Female subjects who are currently breastfeeding or have a positive pregnancy test result at screening;
  35. Subjects deemed by the investigator to have other factors unsuitable for participation in this trial.

MAD

  1. Those diagnosed with type 1, type 2, or other types of diabetes before screening;
  2. Those diagnosed with overweight or obesity caused by other diseases or medications, such as Cushing's syndrome;
  3. History or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia syndrome type 2 (MEN2) during screening, or genetic predisposition to MTC;
  4. Acute, chronic, or suspected pancreatitis during screening, or prior pancreatectomy;
  5. Those diagnosed with any malignancy within 5 years before screening (except for basal cell carcinoma treated curatively and considered cured);
  6. Presence of clinically significant diseases at screening, including but not limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine, oncological, pulmonary, immunological, psychiatric, or cardiovascular disorders (excluding weight-related comorbidities);
  7. Any of the following diseases or medical histories within 6 months prior to screening or before randomization: cardiac insufficiency ( [NYHA] Class III or IV), myocardial infarction, unstable angina, uncontrolled arrhythmias requiring treatment (including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, second- to third-degree atrioventricular block, sick sinus syndrome, etc.), coronary artery bypass grafting, percutaneous coronary intervention (diagnostic angiography allowed), cerebrovascular accident (ischemic stroke, hemorrhagic stroke, ), cirrhosis, etc.;
  8. Diseases or conditions affecting gastric emptying or gastrointestinal nutrient absorption during screening;
  9. Major surgery within 3 months before screening or planned surgery during the study;
  10. History of hypersensitivity to the investigational product or any of its components, or to acetaminophen and its , or allergic constitution (allergy to two or more drugs or foods);
  11. Use of medications (including prescription drugs, over-the-counter medications, Chinese herbal medicines, health supplements, etc.) within 3 months prior to screening that, in the investigator's judgment, significantly affect body weight;
  12. Subjects taking lipid-lowering or antihypertensive medications with unstable doses within 30 days prior to screening;
  13. Individuals who have undergone bariatric surgery prior to screening;
  14. Those with a history of recurrent skin disorders (e.g., urticaria) or skin lesions at the administration site;
  15. Those who received chronic (lasting more than 2 weeks) systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra-articular, or inhaled formulations) within 3 months prior to screening, or systemic glucocorticoid therapy within 1 month prior to screening;
  16. Female subjects with HbA1c \<110 g/L or male subjects with HbA1c \<120 g/L at screening, or any other known condition that interferes with HbA1c measurement;
  17. Those with suicidal behaviors or ideation within 6 months prior to screening;
  18. History of depression or other psychiatric disorders within 6 months prior to screening;
  19. Use of GLP-1R, GLP-1R/GIPR, GLP-1R/GCGR, or GLP-1R/GIPR/GCGR agonists within 6 months prior to screening;
  20. Those with regular alcohol consumption within 3 months prior to screening, defined as more than 14 units of alcohol per week (1 unit = 360 mL beer, 45 mL spirits with 40% alcohol, or 150 mL wine); or those with a positive alcohol breath test during screening; or those unable to comply with the protocol's alcohol restrictions;
  21. Those with a history of drug abuse or illicit drug use within 2 years prior to screening, or those with a positive urine drug screen before the first dose;
  22. Smoking more than 5 cigarettes per day within 3 months prior to screening or inability to abstain from smoking during intensive PK blood sampling;
  23. Those with a history of needle or blood phobia, intolerance to venipuncture, or difficulty in blood collection;
  24. Resting seated blood pressure at screening: systolic blood pressure >160 mmHg or \<90 mmHg, diastolic blood pressure >100 mmHg or \<55 mmHg;
  25. Heart rate at screening >100 beats per minute or \<50 beats per minute;
  26. Those with positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or Treponema pallidum-specific antibody;
  27. Alanine aminotransferase >2 × ULN, aspartate aminotransferase >2 × ULN, alkaline phosphatase >1.5 × ULN, or total bilirubin >1.5 × ULN at screening;
  28. Blood amylase or lipase > ULN at screening;
  29. Those with serum calcitonin ≥20 ng/L at screening;
  30. Fasting triglyceride levels ≥5.6 mmol/L at screening;
  31. Fasting blood glucose ≥7.0 mmol/L or \<3.9 mmol/L at screening; or OGTT 2-hour ≥11.1 mmol/L;
  32. Those with glomerular filtration rate (GFR) \<90 mL/min/1.73m2 at screening;
  33. Fridericia-corrected QT interval (QTcF=QT/RR0.33) >450 ms (for male) or >470 ms (for female) on 12-lead ECG at screening; or severe arrhythmia (second-degree or higher atrioventricular block, ventricular tachycardia, etc.);
  34. Use of strong inhibitors or inducers of hepatic metabolic enzymes (CYP1A2, 2A6, 2C8, 2C19, 3A4, and 3A5) within 4 weeks prior to the first dose, including strong inhibitors such as ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, troleandomycin, etc., or strong inducers such as rifampin, carbamazepine, phenytoin sodium, St. John's wort, etc.;
  35. Consumption of any foods or beverages affecting CYP3A4, CYP2E1, or CYP2D6 metabolic enzymes, such as grapefruit or grapefruit-containing beverages, within 48 hours prior to the first dose;
  36. Ingestion of chocolate, any caffeine-containing or xanthine-rich food or beverage within 48 hours prior to the first dose;
  37. Blood donation ≥200 mL, any component blood donation, or total blood loss ≥200 mL due to any reason within 3 months prior to screening, or a history of blood transfusion or blood product use;
  38. Participation in other clinical trials within 3 months prior to screening (subjects who withdrew from the study before treatment, i.e., were not randomized or did not receive treatment, may be enrolled in this study);
  39. Occurrence of acute illness or concomitant medication use from the signing of the informed consent form until the first dose;
  40. Female subjects who are currently breastfeeding or have a positive pregnancy test result at screening;
  41. Subjects deemed by the investigator to have other factors unsuitable for participation in this trial.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    SAD Stage: HEC-007 Injection

    Administered once

    Drug: HEC-007 injection

  • Placebo comparator
    SAD Stage: Placebo

    Administered once

    Drug: Placebo

  • Experimental
    MAD Stage: HEC-007 injection

    Administered for multiple dose

    Drug: HEC-007 injection

  • Placebo comparator
    MAD Stage: Placebo

    Administered for multiple dose

    Drug: Placebo

Interventions

  • DrugHEC-007 injection

    Single dose escalation of HEC-007 injection in healthy subjects

  • DrugPlacebo

    Single dose of placebo in healthy adults

  • DrugHEC-007 injection

    Multiple dose escalation of HEC-007 injection in Overweight or Obese Subjects

  • DrugPlacebo

    Multiple dose of placebo in Overweight or Obese Subjects

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Time frame: Screening period up to day 43/day 113

  2. The maximum plasma concentration (Cmax)

    Time frame: Post-dose at day 1 to day 43/day 113

  3. Time to maximum plasma concentration (Tmax)

    Time frame: Post-dose at day 1 to day 43/day 113

  4. Terminal half-life (t1/2)

    Time frame: Post-dose at day 1 to day 43/day 113

  5. Apparent clearance (CL/F)

    Time frame: Post-dose at day 1 to day 43/day 113

  6. Apparent volume of distribution (Vz/F)

    Time frame: Post-dose at day 1 to day 43/day 113

  7. Area Under the PlasmaConcentration-TimeCurve (AUC) of HEC-007

    Time frame: Post-dose at day 1 to day 43/day 113

  8. Changes from baseline in Body Weight

    Time frame: Baseline period up to day 43/day 113

  9. Changes from baseline in waist circumference

    Time frame: Baseline period up to day 43/day 113

  10. Changes from baseline in Fasting Plasma Glucose

    Time frame: Baseline period up to day 43/day 113

  11. Changes from baseline in Fasting Insulin

    Time frame: Baseline period up to day 43/day 113

  12. Changes from baseline in fasting blood lipids

    Time frame: Baseline period up to day 43/day 113

07

Study locations

1 of 1 sites recruiting
  • The Second Affiliated Hospital of Anhui Medical University is a Grade A Tertiary General
    Hefei, Anhui 230601, China
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 3, 2025
StartActual
Sep 21, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07102251
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Sep 21, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 5, 2026

Study contacts

Wei Hu, Doctor of Medicine
Contact
ayefygcp@163.com
+8613856086475
Yijun Du, Doctor of Medicine
Contact
2460679232@qq.com
+8613866700016

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion